Effects of (+) SKF 10,047, a sigma-1 receptor agonist, on anxiety,tested in two laboratory models in mice

  1. Navarro Humanes, José Francisco
  2. Beltran Guerrero, David
  3. Cavas Toledo, María
Journal:
Psicothema

ISSN: 0214-9915

Year of publication: 2012

Volume: 24

Issue: 3

Pages: 427-430

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Psicothema

Abstract

Recently, sigma-1 receptor modulators have been considered drugs with an interesting therapeutic potential for the treatment of anxiety. However, there is no clear information in preclinical studies about the possible effects of sigma-1 ligands on anxiety in experimental animal models. Therefore, the present study examined the effects of (+)SKF 10,047 (2-8 mg/kg, ip), a sigma-1 agonist, on anxiety, tested in two classical laboratory models (social interaction test and elevated plus maze). (+)SKF 10,047 (8 mg/kg) produced a significant decrease of social investigation in the "social interaction test", whereas in the "elevated plus maze", the drug (4 and 8 mg/kg) provoked a significant reduction in the number of entries into open arms, as well as in the time spent in this area, as compared with the control group, without affecting motor activity. Overall, these findings indicate that (+)SKF 10,047 exhibits an anxiogenic-like profile in mice. It is suggested that anxiogenic effects of this sigma-1 ligand could be related to its potent ability to modulate diverse neurotransmitter systems involved in anxiety regulation.

Bibliographic References

  • Beltrán, D., Cavas, M., & Navarro, J.F. (2004a). Perfil farmacológico de los receptores sigma. Psiquiatría Biológica, 11, 41-57.
  • Beltrán, D., Cavas, M., & Navarro, J.F. (2004b). Efectos conductuales y potencial terapéutico de los ligandos del receptor sigma-1. Psiquiatría Biológica, 11, 87-100.
  • Beltrán, D., Cavas, M., & Navarro, J.F. (2006). Effects of (+)SKF 10,047, a sigma-1 selective agonist, on isolation-induced aggression in male mice. Methods and Findings in Experimental and Clinical Pharmacology, 28, 601-604.
  • Beltrán, D., & Navarro, J.F. (2007). Función fisiológica de los receptores sigma-1 en el SNC: neuromodulación. Psiquiatría Biológica, 14, 67-76.
  • Bermack, J.E., & Debonnel, G. (2001). Modulation of serotonergic neurotransmission by short-and long-term treatment with sigma ligands. British Journal of Pharmacology, 134, 691-699.
  • Bermack, J.E., & Debonnel, G. (2005). The role of sigma receptors in depression. Journal of Pharmacological Sciences, 97, 317-336.
  • Bowen, W.D. (2000). Sigma receptors: Recent advances and new clinical potentials. Pharmaceutica Acta Helvetiae, 74, 211-218.
  • Brain, P.F., McAllister, K.H., & Walmsley, S.V. (1989). Drug effects on social behaviour. In A.A. Boulton, G.B. Baker & A.J. Greenshaw (Eds.), Neuromethods (pp. 687-739). Nueva Jersey: The Humana Press.
  • Cendan, C.M., Pujalte, J.M., Portillo-Salido, E., Montoliu, L., & Baeyens, J.M. (2005). Formalin-induced pain is reduced in sigma-1 receptor knockout-mice. European Journal of Pharmacology, 511, 73-74.
  • Chevalier, N., Keller, E., & Maurice, T. (2011). Behavioural phenotyping of knockout mice for the sigma-1 (σ1) chaperone protein revealed genderrelated anxiety, depressive-like and memory alterations. Journal of Psychopharmacology, 25, 960-975.
  • File, S.E. (1980). The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. Journal of Neuroscience Methods, 2, 219-238.
  • File, S.E., & Seth, P. (2003). A review of 25 years of the social interaction test. European Journal of Pharmacology, 463, 35-53.
  • Graef S., Schönknecht, P., Sabri, O., & Hegerl, U. (2011). Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings. Psychopharmacology, 215, 205-229.
  • Guitart, X., Codony, X., & Monroy, X. (2004). Sigma receptors: Biology and therapeutic potential. Psychopharmacology, 174, 301-319.
  • Hirata, H., Sonoda, S., Agui, S., Yoshida, M., Ohinata, K., & Yoshikawa, M. (2007). Rubiscolin-6, a delta opioid peptide derived from spinach Rubisco, has anxiolytic effect via activating sigma-1 and dopamine D1 receptors. Peptides, 28, 1998-2003.
  • Karasawa, J., Takahashi, S., Takagi, K., & Horikomi, K. (2002). Effects of sigma(1) receptor ligand MS-377 on D2 antagonists-induced behaviours. Pharmacology Biochemistry and Behavior, 73, 505-510.
  • Kulkarni, S.K., & Dhir, A. (2009). Sigma-1 receptors in major depression and anxiety. Expert Review of Neurotherapeutics, 9, 1021-1034.
  • Lister, R.G. (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 92, 180-185.
  • Mamiya, T., Noda, Y., Noda, A., Hiramatsu, M., Karasawa, K., Kameyama, T., Furukawa, S., Yamada, K., & Nabeshima, T. (2000). Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice. Neuropharmacology, 39, 2391-2398.
  • Müller, W.E., Siebert, B., Holoubek, G., & Gentsch, C. (2004). Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Pharmacopsychiatry, 37 (suppl. 3), 189-197.
  • Navarro, J.F., & Manzaneque, J.M. (1999). Behavioral profile of amisulpride in agonistic encounters between male mice. Aggressive Behavior, 25, 225-232.
  • Navarro, J.F., & Pedraza, C. (1996). An ethopharmacological assessment of the effects of gammahydroxybutyrate (GHB) on agonistic interactions in male mice. Medical Science Research, 24, 817-819.
  • Navarro, J.F., Rivera, A., Maldonado, E., Cavas, M., & De la Calle, A. (2004). Anxiogenic-like activity of 3,4-methylenedioxymethamphetamine ("Ecstasy") in the social interaction test is accompanied by an increase of c-fos expression in mice amygdala. Progress in NeuroPsychopharmacology and Biological Psychiatry, 28, 249-254.
  • Navarro, J.F., Luna, G., & García, F.B. (2005). Acute and subchronic effects of agmatine on anxiety tested in the elevated plus maze in male mice. Psicothema, 17, 325-328.
  • Navarro, J.F., Burón, E., & Martín-López, M. (2006). Anxiolyticlike activity of SB-205384 in the elevated plus maze test in mice. Psicothema, 18, 100-104.
  • Noda, Y., Kamei, H., & Nabeshima, T. (1999). Sigma-receptor ligands and anti-stress actions. Nippon Yakurigaku Zasshi, 114, 43-49.
  • Sabino, V., Cottone, P., Parylak, S.L., Steardo, L., & Zorrilla, E.O. (2009). Sigma-1 receptor knockout mice display a depressive-like phenotype. Behavioural Brain Research, 198, 472-476.
  • Sánchez, C., Arnt, J., Costall, B., Kelly, M.E., Meier, E., Naylor, R.J., & Perregaard, J. (1997). The selective sigma-2 ligand Lu 28-179 has potent anxiolytic-like effects in rodents. The Journal of Pharmacology and Experimental Therapeutics, 283, 1323-1332.
Data source: Dialnet